Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1

Conditions

Immunoglobulin Light-chain Amyloidosis 1

Interventions

Dexamethasone 7Calcium Dobesilate 5Filgrastim 4Cyclophosphamide 4miridesap 3ixazomib 3dexamethasone acetate 3dexamethasone 21-phosphate 3auricularum 3Peripheral Blood Stem Cell Transplantation 3Bortezomib 3venetoclax 2Tacrolimus 2Methylprednisolone 2Amifostine 2sargramostim 1pyroxamide 1pomalidomide 1nelarabine 1melflufen 1isatuximab 1fludarabine phosphate 1daratumumab 1X-Rays 1Topotecan 1Tetradecanoylphorbol Acetate 1Technetium Tc 99m Pyrophosphate 1Technetium 1Sunitinib 1Specimen Handling 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Immunoglobulin Light-chain Amyloidosis × melflufen × Clear all
NCT04115956 2022-03-28

A Clinical Study of Melphalan Flufenamide (Melflufen) and Dexamethasone for Patients With Immunoglobulin Light Chain (AL) Amyloidosis

Oncopeptides AB

Phase 1 Terminated
6 enrolled
Plasma cell

Immunoglobulin Light-chain Amyloidosis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡